Vogel Leatrice N, Roberts Anjeanette, Paddock Christopher D, Genrich Gillian L, Lamirande Elaine W, Kapadia Sagar U, Rose John K, Zaki Sherif R, Subbarao Kanta
Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA.
Vaccine. 2007 Mar 8;25(12):2173-9. doi: 10.1016/j.vaccine.2006.11.055. Epub 2006 Dec 11.
The causative agent of Severe Acute Respiratory Syndrome (SARS) was identified as a coronavirus (CoV) following the outbreak of 2002-2003. There are currently no licensed vaccines or treatments for SARS-CoV infections. Potential prevention and control strategies that show promise in vitro must be evaluated in animal models. The aged BALB/c mouse model for SARS supports a high level of viral replication in association with clinical illness and disease that mimics SARS in the elderly. We tested two preventive strategies, vaccination and passive transfer of serum antibody, to determine the extent of protection achieved against SARS-CoV challenge in this model. These approaches were able to achieve or induce antibody titers sufficient to reduce viral load, protect from weight loss and reduce or eliminate histopathologic changes in the lungs of aged mice. This study validates the utility of the aged BALB/c mouse model for evaluation of the efficacy of vaccines and immunoprophylaxis.
2002年至2003年严重急性呼吸综合征(SARS)疫情爆发后,其病原体被确定为一种冠状病毒(CoV)。目前尚无针对SARS-CoV感染的许可疫苗或治疗方法。在体外显示有前景的潜在预防和控制策略必须在动物模型中进行评估。老年BALB/c小鼠SARS模型支持高水平的病毒复制,并伴有类似于老年人SARS的临床疾病。我们测试了两种预防策略,即疫苗接种和血清抗体的被动转移,以确定在该模型中针对SARS-CoV攻击所实现的保护程度。这些方法能够达到或诱导足够的抗体滴度,以降低病毒载量,防止体重减轻,并减少或消除老年小鼠肺部的组织病理学变化。本研究验证了老年BALB/c小鼠模型在评估疫苗效力和免疫预防方面的实用性。